Stomatitis

(redirected from amlexanox)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

stomatitis

[‚stō·mə′tīd·əs]
(medicine)
Inflammation of the soft tissues in the mouth.

Stomatitis

 

inflammation of the oral mucosa accompanied by degenerative changes in the oral cavity. In humans, stomatitis may be caused by mechanical, thermal, chemical, or physical injury, hypovitaminosis, diabetes mellitus, diseases of the cardiovascular, nervous, hematopoietic, and digestive systems, acute infections (for example, measles, scarlet fever, and diphtheria), chronic infections (for example, tuberculosis), poisoning, and parasitic fungi (for example, thrush).

The factors that cause traumatic stomatitis include deposits of dental calculus, decayed carious teeth, poorly made prostheses and fillings, foreign objects, burns produced by hot food, and the action of alkalies and acids. A catarrhal process develops after short exposure to an injurious factor, with the mucous membrane becoming hyperemic and edematous and bleeding easily. Prolonged exposure results in the formation of ulcers, around which inflammatory phenomena develop.

Stomatitis caused by systemic diseases is characterized by the appearance of aphthae on the oral mucosa; it may be acute or chronic. Acute stomatitis aphthosa usually occurs in children suffering from gastrointestinal diseases, diatheses, or viral diseases. The body temperature is high, and aphthae surrounded by a bright red border appear on the mucosa of the gums, lips, and palate. There is profuse salivation, and the submaxillary lymph nodes become enlarged and tender. The disease lasts seven to ten days. Chronic recurrent stomatitis aphthosa is characterized by the periodic appearance of solitary aphthae on the buccal mucosa, the lateral surface of the tongue, and the lower lip. The bottoms of the aphthae are covered with a grayish yellow coating. The lymph nodes are usually not enlarged. The disease lasts five to ten days, after which the aphthae epithelize or are transformed into ulcers.

Ulcerative stomatitis commonly accompanies acute enterocolitis, gastric ulcer, and mercury and bismuth poisoning. It may result from tonsillitis or influenza. Ulcers may appear over the entire mucosa. A disagreeable odor emanates from the mouth, and salivation is profuse. With blood diseases (leukemias), aphthae appear on the oral mucosa and tonsils; the aphthae are eventually transformed into ulcers. Radiation sickness is characterized by the same symptoms.

Preventive and therapeutic measures include good oral hygiene, the elimination of the causes of the disease, rinsing of the mouth with a salt solution or boric acid (depending on the pH of the oral environment), physical therapy, and the application of sea-buckthorn oil.

REFERENCE

Rybakov, A. I. Stomatity. Moscow, 1964.
A. I. RYBAKOV
In animals. Stomatitis results from mechanical, thermal, or chemical factors (primary stomatitis) or accompanies such infectious diseases as foot-and-mouth disease and stachybotryotoxico-sis (secondary stomatitis). A diseased animal refuses to eat. The disease is manifested by frothy salivation, mucosal lesions, and a putrid mouth odor.
Treatment methods include irrigating the oral mucosa with disinfectants and astringents. Specific treatment is indicated in cases of secondary stomatitis.
References in periodicals archive ?
Saltiel is teaming up with clinical-trial specialists at U-M to test whether amlexanox will be useful for treating obesity and diabetes in humans.
LexaGard(TM) is a proprietary formulation of amlexanox in a mucoadhesive hydrogel formulation designed for treatment of conditions of the upper gastrointestinal tract including Barrett's esophagus and esophagitis.
stated, "We are pleased that this agreement consolidates marketing of the Amlexanox range of products with a significant European company with subsidiaries in the major Western European markets and Eastern Europe.
We also believe that, due to the fact that amlexanox is already marketed for a similar indication and has an excellent safety profile, only an abbreviated Phase III package on mucositis will be necessary to gain FDA approval.
Currently amlexanox 5% paste is approved by the FDA for the treatment of canker sores.
These letters of intent and licensing agreements are expected to accelerate the global marketing of amlexanox and hence the royalty payments to Access.
Paladin will immediately commence the registration process for amlexanox 5% paste in Canada and bear all costs associated with the filing and prosecution of the product license application including user fees.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties, including but not limited to statements made relating to projected product revenues, potential additional licensing arrangements, the amlexanox approval process, projections from our licensing partners for amlexanox sales, expected milestone payments, and the markets for amlexanox paste and OraDisc(TM) A.
Market surveys indicate the market potential for amlexanox in the UK could exceed $25 million which is proportionate in size to the estimated potential market in the U.
These activities together with revenues projected from amlexanox, the FDA approved product, are expected to assist the Company to achieve its objective of near-term profitability.
We recently entered into an agreement for amlexanox and OraDisc A with Discus Dental and we are optimistic that this technology will continue to produce a stream of new product opportunities.